Evidence map›Paper›PMID 39015347›Full record

ArticleOpen forum infectious diseases2024

Discrimination of the Veterans Aging Cohort Study Index 2.0 for Predicting Cause-specific Mortality Among Persons With HIV in Europe and North America.

Julie Ambia, Suzanne M Ingle, Kathleen McGinnis, Nikos Pantazis, Michael J Silverberg, Linda Wittkop, Katharina Kusejko, Heidi Crane, Ard van Sighem, Mario Sarcletti and 15 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Julie AmbiaPopulation Health Sciences, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0001-9883-4561
Suzanne M InglePopulation Health Sciences, University of Bristol, Bristol, UK.
Kathleen McGinnisVA Connecticut Healthcare System, US Department of Veteran Affairs, West Haven, Connecticut, USA.
Nikos PantazisDepartment of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.ORCID https://orcid.org/0000-0001-9322-1395
Linda WittkopUniversity of Bordeaux, INSERM, Institut Bergonié, BPH, U1219, CIC-EC 1401, F-33000, Bordeaux, France.ORCID https://orcid.org/0000-0003-2403-0960
Katharina KusejkoDivision for Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-4638-1940
Heidi CraneDivision of Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA.
Ard van SighemStichting HIV Monitoring, Amsterdam, Netherlands.
Mario SarclettiDepartment of Dermatology and Venereology, Medical University of Innsbruck, Innsbruck, Austria.
Alessandro Cozzi-LepriInstitute for Global Health, University College London, London, UK.
Pere DomingoDepartment of Infectious Diseases, Santa Creu i Sant Pau Hospital, Barcelona, Spain.ORCID https://orcid.org/0000-0003-1138-5770
Inma JarrinNational Centre of Epidemiology, Carlos III Health Institute, Madrid, Spain.
Christoph WyenDepartment I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Mojgan HessamfarDepartment of Internal Medicine and Infectious Disease, Bordeaux University Hospital F-33000, Bordeaux, France.
Lei ZhangPopulation Health Sciences, University of Bristol, Bristol, UK.
Matthias CavassiniInfectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0003-0933-7833
Juan BerenguerHospital General Universitario Gregorio Marañón, IiSGM, CIBERINFEC, Madrid, Spain.ORCID https://orcid.org/0000-0001-8541-8200
Timothy R SterlingDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0002-4822-6979
Peter ReissStichting HIV Monitoring, Amsterdam, The Netherlands.
Sophie AbgrallAPHP, Hôpital Béclère, Service de Médecine Interne, Clamart, France.
M John GillDepartment of Medicine, University of Calgary, South Alberta HIV Clinic, Calgary, Alberta, Canada.
Amy JusticeVA Connecticut Healthcare System, US Department of Veteran Affairs, West Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-0139-5502
Jonathan A C SternePopulation Health Sciences, University of Bristol, Bristol, UK.
Adam TrickeyPopulation Health Sciences, University of Bristol, Bristol, UK.ORCID https://orcid.org/0000-0003-3462-2898

Funding

1/3 Collaborative Research in HIV/AIDS, Alcohol, and Related Comorbidities (COMpAAAS) Tripartite: ART-CC, KP, and VAU01AA026209 · NIAAA · UNIVERSITY OF BRISTOL · PI STERNE, JONATHAN · 2017 to 2021
$2.2M
NIAAA NIH HHS U01 AA026209
6 · The paper itself

Abstract

Background: Predicting cause-specific mortality among people with HIV (PWH) could facilitate targeted care to improve survival. We assessed discrimination of the Veterans Aging Cohort Study (VACS) Index 2.0 in predicting cause-specific mortality among PWH on antiretroviral therapy (ART). Methods: Using Antiretroviral Therapy Cohort Collaboration data for PWH who initiated ART between 2000 and 2018, VACS Index 2.0 scores (higher scores indicate worse prognosis) were calculated around a randomly selected visit date at least 1 year after ART initiation. Missingness in VACS Index 2.0 variables was addressed through multiple imputation. Cox models estimated associations between VACS Index 2.0 and causes of death, with discrimination evaluated using Harrell's C-statistic. Absolute mortality risk was modelled using flexible parametric survival models. Results: Of 59 741 PWH (mean age: 43 years; 80% male), the mean VACS Index 2.0 at baseline was 41 (range: 0-129). For 2425 deaths over 168 162 person-years follow-up (median: 2.6 years/person), AIDS (n = 455) and non-AIDS-defining cancers (n = 452) were the most common causes. Predicted 5-year mortality for PWH with a mean VACS Index 2.0 score of 38 at baseline was 1% and approximately doubled for every 10-unit increase. The 5-year all-cause mortality C-statistic was .83. Discrimination with the VACS Index 2.0 was highest for deaths resulting from AIDS (0.91), liver-related (0.91), respiratory-related (0.89), non-AIDS infections (0.87), and non-AIDS-defining cancers (0.83), and lowest for suicides/accidental deaths (0.65). Conclusions: For deaths among PWH, discrimination with the VACS Index 2.0 was highest for deaths with measurable physiological causes and was lowest for suicide/accidental deaths.

Indexed as

absolute riskC-statisticmultiple imputationprognosisVACS

Identifiers

PMID39015347
PMCPMC11249920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.